Multiple sclerosis and its treatment

Journal of the Royal College of Physicians of London

Volumn 33, Issue 4, 1999, Pages 315-322

  Giovannoni, Gavin ^a   Miller, David H ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMANTADINE; AZATHIOPRINE; BACLOFEN; BOTULINUM TOXIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; GANCICLOVIR; GLATIRAMER; IMMUNOGLOBULIN; INTERLEUKIN 10; MATRIX METALLOPROTEINASE INHIBITOR; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; MYELIN; MYELIN ASSOCIATED GLYCOPROTEIN; MYELIN BASIC PROTEIN; PENTOXIFYLLINE; PHENOL; RECOMBINANT BETA INTERFERON; RETINOIC ACID; SALAZOSULFAPYRIDINE; TACROLIMUS; THALIDOMIDE; TIZANIDINE; VALACICLOVIR; VITAMIN D;

AUTOIMMUNITY; DISEASE COURSE; DRUG EFFICACY; FLU LIKE SYNDROME; HELPER CELL; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PLASMAPHERESIS; RELAPSE; REVIEW; SIDE EFFECT; SKIN NECROSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MULTIPLE SCLEROSIS; T-LYMPHOCYTES;

EID: 0032841108     PISSN: 00358819     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Martin R, McFarland HF. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 1995;32:121-82.
2. Challoner PB, Smith KT, Parker JD, Macleod DL, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci USA 1995;92:7440-4.
3. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicentre, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
4. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, et al. The Multiple Sclerosis Collaborative Research Group. Intramuscular Interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
5. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352: 1498-504.
6. European Study Group on Interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon-1 b in treatment of secondary progressive multiple sclerosis. Lancet 1998:352:1491-7.
7. Freedman MS. Dose-dependent clinical and magnetic resonance imaging efficacy of Interferon beta-1 a in multiple sclerosis. Ann Neurol 1998;44:992.
8. Johnson KP, Brooks BR, Cohen JA, Ford CC, et al. The Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-76.
9. Johnson KP, Brooks BF, Cohen JA, Ford CC, et al. The Copolymer 1 Multiple Sclerosis Study Group. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998; 50:701-8.
10. Yudkin PI, Ellison GW, Ghezzi A, Goodkin DE, et al. Overview of azathioprine in multiple sclerosis. Lancet 1991 ;338: 1051-5.
11. Palace J, Rothwell P. New treatments and azathioprine in multiple sclerosis. Lancet 1997;350:261.
12. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997;337:536-42.
13. The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann Neurol 1990;27:591-605.
14. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997;349:589-93.
15. Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Van Dyke C. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995;37:30-40.
16. Hauser SL, Dawson DM, Lehrich JR, Beal MF, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983;308:173-80.
17. Goodkin DE, Plencner S, Palmer-Saxerud J, Teetzen M, Hertsgaard D. Cyclophosphamide in chronic progressive multiple sclerosis: maintenance vs non-maintenance therapy. Arch Neurol 1987;44:823-7.
18. Weiner HL, Mackin GA, Orav EJ, Hafler DA, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993;43:910-8.
19. The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991;337: 441-6.
20. Noseworthy JH, O'Brien P, Erickson BJ, Lee D, et al. The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology 1998;51:1342-52.
21. van Oosten BW, Lai M, Hodgkinson S, Barkhof F, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 1997;49:351-7.
22. Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511-6.
23. Alam SM, Kyriakides T, Lawden M, Newman PK. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993;56:1219-20.
24. Barnes D, Hughes RA, Morris RW, Wade-Jones O, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997;349:902-6.
25. Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998;51:529-34.
26. The United Kingdom Tizanidine Trial Group. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 1994;44(Suppl 9): S70-8.
27. Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology 1994;44(Suppl 9):S34-42; discussion: 42-3.
28. Ordia JI, Fischer E, Adamski E, Spatz EL. Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. J Neurosurg 1996;85:452-7
29. Snow BJ, Tsui JK, Bhatt MH, Varelas M, et al. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990;28:512-5.
30. Dasgupta P, Haslam C, Goodwin R, Fowler CJ. The 'Queen Square bladder stimulator': a device for assisting emptying of the neurogenic bladder. Br J Urol 1997;80:234-7.
31. De Ridder D, Chandiramani V, Dasgupta P, Van Poppel H, et al. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term follow up. J Urol 1997;158:2087-92.
32. Valiquette G, Herbert J, Maede-D'Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol 1996;53:1270-5.
33. Hoverd PA, Fowler CJ. Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;65:778-80.
34. Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, et al. Medicated Urethral System for Erection (MUSE) Study Group. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997;336:1-7.
35. Padma-Nathan H, Steers WD, Wicker PA. Sildenafil Study Group. Efficacy and safety of oral Sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Int J Clin Pract 1998;52:375-9.
36. Krupp LB, Coyle PK, Doscher C, Miller A, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995;45: 1956-61.
37. Bever CT. The current status of studies of aminopyridines in patients with multiple sclerosis. Ann Neurol 1994;36(Suppl): S118-21.
38. Andersen G, Vestergaard K, Riis JO. Citalopram for post-stroke pathological crying. Lancet 1993;342:837-9.
39. Nahas Z, Arlinghaus KA, Kotrla KJ, Clearman RR, George MS. Rapid response of emotional incontinence to selective serotonin reuptake inhibitors. J Neuropsychiatry Clin Neurosci 1998;10: 453-5.
40. Dworkin RH, Bates D, Millar JH, Paty DW. Linoleic acid and multiple sclerosis: a reanalysis of three double-blind trials, Neurology 1984;34:1441-5.
41. Freeman JA, Langdon DW, Hobart JC, Thompson AJ. Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community? Neurology 1999;52:50-6.